Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

*BMJ Open Resp Res*

Supplementary material:

**Factors associated with treatment outcome at the end of treatment using univariate logistic regression analysis**

| Independent variables (n=98) | | Treatment outcome | | OR (0.95% CI) | p-value |
|---|---|---|---|---|---|
| | | Successful (n=85) | Unsuccessful (n=13) | | |
| **\*Age** | | 29 (22-40) | 33.5 (25- 44.7) | 0.97 (0.95-1.04) | 0.896 |
| **\*Body weight at admission** | | 48 (45-57.5) | 47.0 (36.2-60.5) | 1.03 (0.97-1.09) | 0.347 |
| **\*Body weight after 8 months (n=85)** | | 56 (47-60) | 43.2 (10.5-NA) | 1.08 (0.98-1.18) | 0.140 |
| **\*Levofloxacin dose, mg/kg** | | 15.6 (13.5-17.0) | 16 (12.92-18.35) | 0.99 (0.80-1.22) | 0.929 |
| **Gender** | | | | | |
| | Male | 48 (56.5) | 7 (58.3) | 0.93 (0.27-3.15) | |
| | Female | 37 (43.5) | 5 (41.7) | Ref | 0.903 |
| **Prior anti-TB therapy** | | | | | |
| | No | 8 (9.4) | 2 (16.7) | Ref | 0.446 |
| | Yes | 77 (90.6) | 10 (83.3) | 1.92 (0.35-10.36) | |
| **\*Days of sputum conversion (n=75)** | | 90 (60-105) | 45 (30-112.5) | 1.01 (0.98-1.04) | 0.321 |
| **\*Days of culture conversion (n=81)** | | 90 (60-90) | 30 (30-37.5) | 1.09 (1.03-1.15) | 0.002 |
| **Alcohol abuse (n=84)** | | | | | |
| | No | 62 (82.7) | 8 (88.9) | Ref | |
| | Yes | 13 (17.3%) | 1 (11.1%) | 1.67 (0.19-14.51) | 0.639 |
| **Chest Radiography (n=80)** | | | | | |
| | Cavitary lesion | 5 (5.9) | 1 (8.3) | 0.80 (0.07-8.75) | 0.855 |
| | Bilateral pulmonary involvement with cavitary lesion | 10 (11.8) | 1 (8.3) | 1.60 (0.16-16.13) | 0.690 |
| | Bilateral pulmonary involvement | 32 (37.6) | 2 (16.7) | 2.6 (0.43-15.12) | 0.300 |
| | Non cavitary non-bilateral pulmonary involvement | 25 (29.4) | 4 (33.3) | Ref | |

Data are presented as n (%), unless otherwise stated: *median (interquartile ranges). OR: odds ratio; CI: confidence intervals